Table 1.

Effect of 10 years' treatment with chlorpropamide, glibenclamide, or insulin on patients with newly diagnosed type 2 diabetes

Any diabetes related end points * (%)Microvascular disease (%)Individual macrovascular disease end points Median haemoglobin A1c (%)
Dietary advice plus chlorpropamide, glibenclamide, or insulin35.38.2No significant difference between the groups for any of the individual end points Chlorpropamide 6.7; glibenclamide 7.2; insulin 7.1
Dietary advice only38.510.67.9
Relative risk reduction8.222.6Significantly lower for all drugs compared with dietary advice
Absolute risk reduction3.2 §2.4
No needed to treat for 10 years to prevent one event3142
  • * Sudden death, death from hyperglycaemia or hypoglycaemia, fatal or non-fatal myocardial infarction, angina, heart failure, stroke, renal failure, amputation, vitreous haemorrhage, retinal photocoagulation, blindness in one eye, cataract extraction.

  • † Deaths related to diabetes, all cause mortality, myocardial infarction, stroke, blindness, renal failure, or neurological events.

  • ‡ P value for myocardial infarctions was 0.052 (dietary advice plus drug treatment 14.2% vdietary advice 16.3%). However, because the study was continued after the initial results showed no differences, a breakpoint for significance of 0.05 is debatable.

  • § 2.7% of this 3.2% was due to a significant reduction in retinal photocoagulation.